ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks Jim Cramer talked about, along with market froth. When a caller asked about the stock during the lightning round, Cramer said:
Okay, now that… see what happens, I think is you already had that. That moved gigantically. It’s had a giant run off this FDA meeting, and I really think that you have to take profits in some of that, not all of it, but some of it, because it’s up so big.
Photo by Artem Podrez on Pexels
ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. During the May 19, 2025, episode, Cramer was asked about the stock by a caller, and he replied:
IBRX is not a great stock, ImmunityBio. I’ve looked at it for a very, very long time. I don’t like the fact that they are, they’ve been losing money forever. I am not in their camp.
It is important to note that since the above comment was aired, the company’s stock has gained over 130%. Furthermore, the stock is up over 220% year-to-date.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
